Product nameAnti-Eph receptor A2 antibody [EPR17660-120]
See all Eph receptor A2 primary antibodies
DescriptionRabbit monoclonal [EPR17660-120] to Eph receptor A2
Tested applicationsSuitable for: WB, ICC/IF, IP, Flow Cytmore details
Species reactivityReacts with: Mouse, Rat
Recombinant fragment within Mouse Eph receptor A2 aa 300-550. The exact sequence is proprietary.
Database link: Q03145
- WB: NIH/3T3, L-929, F9 and C6 whole cell lysates. ICC/IF: NIH/3T3 cells. Flow Cyt: NIH/3T3 cells. IP: NIH/3T3 whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 0.05% BSA, 40% Glycerol, PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab185156 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 130 kDa (predicted molecular weight: 109 kDa).|
FunctionReceptor for members of the ephrin-A family. Binds to ephrin-A1, -A3, -A4 and -A5. Plays an important role in angiogenesis and tumor neovascularization. The recruitement of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly (By similarity). Induces apoptosis in a p53/TP53-independent, caspase-8-dependent manner.
Tissue specificityExpressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g., skin, intestine, lung, and ovary.
Involvement in diseaseGenetic variations in EPHA2 are the cause of susceptibility to cataract cortical age-related type 2 (ARCC2) [MIM:613020]. A developmental punctate opacity common in the cortex and present in most lenses. The cataract is white or cerulean, increases in number with age, but rarely affects vision.
Defects in EPHA2 are the cause of cataract posterior polar type 1 (CTPP1) [MIM:116600]. A subcapsular opacity, usually disk-shaped, located at the back of the lens. It can have a marked effect on visual acuity.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily.
Contains 2 fibronectin type-III domains.
Contains 1 protein kinase domain.
Contains 1 SAM (sterile alpha motif) domain.
modificationsActivated by EFNA1 via tyrosine phosphorylation. Phosphorylated residues Tyr-588 and Tyr-594 are required for binding VAV2 and VAV3 while phosphorylated residues Tyr-735 and Tyr-930 are required for binding PI3-kinase p85 subunit. These phosphorylated residues are critical for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which transduce downstream signaling to activate RAC1 GTPase and endothelial cell migration. They also play a critical role in transducing EPHA2 signaling in vascular endothelial cells during tumor angiogenesis.
- Information by UniProt
- ARCC2 antibody
- AW545284 antibody
- CTPA antibody
All lanes : Anti-Eph receptor A2 antibody [EPR17660-120] (ab185156) at 1/1000 dilution
Lane 1 : NIH/3T3 (mouse embryo fibroblast cell line) whole cell lysate
Lane 2 : L-929 (mouse connective tissue fibroblast cell line) whole cell lysate
Lane 3 : F9 (mouse embryonic testicular cancer cell line) whole cell lysate
Lane 4 : C6 (rat glial tumor cell line) whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 109 kDa
Observed band size: 130 kDa why is the actual band size different from the predicted?
Exposure times Lane 1-3: 3 seconds; Lane 4: 3 minutes.
Blocking/Dilution buffer: 5% NFDM/TBST.
Immunofluorescent analysis of 100% methanol-fixed NIH/3T3 (mouse embryonic fibroblast cell line) cells labeling Eph receptor A2 with ab185156 at 1/50 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing membranous staining on NIH/3T3 cells.
The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
Flow cytometric analysis of NIH/3T3 (mouse embryonic fibroblast cell line) cell line labeling Eph receptor A2 with ab185156 at 1/50 dilution (red) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.
Total viable cells were gated for the FC image.
Eph receptor A2 was immunoprecipitated from 0.35 mg of NIH/3T3 (mouse embryonic fibroblast cell line) lysate with ab185156 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab185156 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Lane 1: NIH/3T3 whole cell lysate 10 µg (Input).
Lane 2: ab185156 IP in NIH/3T3 whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab185156 in NIH/3T3 whole cell lysate.
Exposure time: 10 seconds.
Blocking/Dilution buffer: 5% NFDM/TBST.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab185156 has been referenced in 1 publication.
- Li G et al. miR-141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression. Mol Med Rep 18:1395-1404 (2018). PubMed: 29901110